Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C

Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression

(2021) Sujun Chen et al.   NATURE CELL BIOLOGY

Clinical and Biological Features of Neuroendocrine Prostate Cancer

(2021) Yasutaka Yamada et al.   Current Oncology Reports

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

(2021) Yundong He et al.   Nature Communications

Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial

(2021) A.A. Hamid et al.   ANNALS OF ONCOLOGY

A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer

(2021) Erik Bovinder Ylitalo et al.   Clinical Epigenetics

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

(2020) Philip Cornford et al.   EUROPEAN UROLOGY

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer

(2019) William S. Chen et al.   EUROPEAN UROLOGY

Genomic correlates of clinical outcome in advanced prostate cancer

(2019) Wassim Abida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor

(2019) Elin Thysell et al.   Molecular Oncology

Towards precision oncology in advanced prostate cancer

(2019) Sheng-Yu Ku et al.   Nature Reviews Urology

Genomics of lethal prostate cancer at diagnosis and castration resistance

(2019) Joaquin Mateo et al.   JOURNAL OF CLINICAL INVESTIGATION

Breast cancer lung metastasis: Molecular biology and therapeutic implications

(2018) Liting Jin et al.   CANCER BIOLOGY & THERAPY

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

(2018) David A. Quigley et al.   CELL

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas

(2018) Shuang G Zhao et al.   CLINICAL CANCER RESEARCH

Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response

(2017) Erik Bovinder Ylitalo et al.   EUROPEAN UROLOGY

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy

(2017) Shuang G. Zhao et al.   JAMA Oncology

Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome

(2016) S. You et al.   CANCER RESEARCH

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

(2016) Himisha Beltran et al.   NATURE MEDICINE

Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype

(2016) Sofia Halin Bergström et al.   NEOPLASIA

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

The Molecular Taxonomy of Primary Prostate Cancer

(2015) Adam Abeshouse et al.   CELL

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling

(2014) Eric A. Klein et al.   EUROPEAN UROLOGY

Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy

(2013) Nicholas Erho et al.   PLoS One

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study

(2011) Jack Cuzick et al.   LANCET ONCOLOGY